A 60-year-old with newly diagnosed H. pylori receives bismuth quadruple therapy. He asks about clarithromycin triple therapy. Why is it discouraged em...

Question

A 60-year-old with newly diagnosed H. pylori receives bismuth quadruple therapy. He asks about clarithromycin triple therapy. Why is it discouraged empirically?

Accepted Answer

High clarithromycin resistance reduces efficacy

Answer

Lower pill burden

Answer

It causes more diarrhoea

Answer

It is more expensive

Answer

It requires IV therapy

us-abfm MCQ (SBA): H. pylori-Resistance

A 60-year-old with newly diagnosed H. pylori receives bismuth quadruple therapy. He asks about clarithromycin triple therapy. Why is it discouraged empirically?